Get the Stockscreener App
5.05
1.81%
0.09
Alpha Tau Medical Ltd stock is traded at $5.05, with a volume of 171.94K.
It is up +1.81% in the last 24 hours and up +27.20% over the past month.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
See More
Previous Close:
$4.96
Open:
$4.99
24h Volume:
171.94K
Relative Volume:
1.90
Market Cap:
$430.58M
Revenue:
-
Net Income/Loss:
$-29.64M
P/E Ratio:
-11.74
EPS:
-0.43
Net Cash Flow:
$-39.43M
1W Performance:
+29.82%
1M Performance:
+27.20%
6M Performance:
+64.50%
1Y Performance:
+64.50%
1-Day Range:
$4.79
$5.10
1-Week Range:
$3.84
$5.10
52-Week Range:
$2.30
$5.10
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
5.05 | 422.91M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-23 | Initiated | Citigroup | Buy |
| Apr-24-23 | Initiated | H.C. Wainwright | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-08-22 | Initiated | Piper Sandler | Overweight |
| Apr-04-22 | Initiated | Citigroup | Buy |
Alpha Tau Medical Ltd Stock (DRTS) Latest News
Alpha Tau Medical up sharply as brain cancer trial beginsGlobes - Globes - Israel Business News
Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly? - simplywall.st
Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau Medical (NASDAQ:DRTS) Price Target Lowered to $7.00 at Citigroup - Defense World
What's Next For Alpha Tau: Major Milestones Expected Through Early 2026 - RTTNews
Alpha Tau Medical (NASDAQ:DRTS) Given New $7.00 Price Target at Citigroup - MarketBeat
Taking on analysts’ expectations and winning: Alpha Tau Medical Ltd (DRTS) - setenews.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock By Investing.com - Investing.com Canada
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock - Investing.com
Promising Clinical Developments and Innovative Technology Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau price target lowered to $7 from $8 at Citi - TipRanks
Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough - Nasdaq
Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading? - Benzinga
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma - Imaging Technology News
Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University - marketscreener.com
Alpha Tau announces first patient treated in study using Alpha DaRT tech - TipRanks
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks
Alpha Tau (Nasdaq: DRTS) gives first Alpha DaRT brain treatment in OSU GBM study - Stock Titan
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - Sahm
Alpha Tau treats first US patient with Alpha DaRT for glioblastoma - MSN
Alpha Tau Medical (NASDAQ:DRTSW) Trading 6.9% Higher – Here’s What Happened - Defense World
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform international peersMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Is Alpha Tau Medical Ltd. Equity Warrant stock a smart buy before Fed meeting2025 Technical Overview & Reliable Breakout Forecasts - Newser
Why Alpha Tau Medical Ltd. Equity Warrant stock is popular among millennialsMarket Risk Analysis & Low Risk Investment Opportunities - Newser
Will Alpha Tau Medical Ltd. stock rally after Fed decisionsJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - TipRanks
Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium - TipRanks
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - The Manila Times
Alpha Tau Announces Presentation of Two Alpha DaRT - GlobeNewswire
Alpha Tau Medical to present pancreatic cancer research at 2026 ASCO symposium - MSN
How Alpha Tau Medical Ltd. stock benefits from global expansionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Alpha Tau Medical Ltd. Receives FDA Approval to Initiate A Trial for Patients with Locally Recurrent Prostate Cancer - marketscreener.com
Alpha Tau receives FDA approval to initiate a trial for patients with locally recurrent prostate cancer - marketscreener.com
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Trial - TipRanks
Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - The Manila Times
Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer - Stock Titan
Alpha Tau to Participate in December Investor Conferences - The Manila Times
COO Gat Files To Sell 16,000 Of Alpha Tau Medical Ltd [DRTS] - TradingView
Alpha Tau (NASDAQ: DRTS) to present at Piper Sandler, Sidoti investor events in Dec 2025 - Stock Titan
What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Momentum & Safe Capital Growth Stock Tips - moha.gov.vn
HC Wainwright Has Negative Outlook for DRTS FY2025 Earnings - MarketBeat
What is HC Wainwright’s Forecast for DRTS FY2025 Earnings? - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Reports Q3 2025 Progress and Financials - MSN
Alpha Tau reports Q3 EPS (32c), consensus (12c) - MSN
Alpha Tau Eyes Year-End Japanese Clearance For Alpha DaRT Treatment In Recurrent Head & Neck Cancer - Nasdaq
Alpha Tau Medical Ltd Stock (DRTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):